AB INITIO ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER TO DISCOVER GPCR ACTIVATING ANTIBODIES
December 13, 2016
Ab Initio entered into a research collaboration and license agreement with Pfizer for an undisclosed GPCR target, along with a strategic investment by Pfizer. We are honored to have Will Somers, Vice President of Biomedicines Design at Pfizer join our Scientific Advisory Board. Check out the story at Fierce Biotech, and our full release for additional details here.
AB INITIO's Technology are featured at the First Annual CRI-CIMT-EATI-AACR Immunotherapy Conference
September 18, 2015
Ab Initio's technology and powerful engineering approach were showcased at the year's biggest cancer immunotherapy meeting. The development and validation of our unique small protein therapeutic against the PD-1/PD-L1 pathway were also highlighted by the official blog of the American Association of Cancer Research, and the AACR Newsroom.